Construction for Prostate Cancer Patients with a History of Malignancy by Professor Kan Gong ‘s Team | AUA 2024

Construction for Prostate Cancer Patients with a History of Malignancy by Professor Kan Gong ‘s Team | AUA 2024

2024.06.24
With advancements in cancer screening, diagnosis, and treatment, the survival period of cancer patients has significantly increased. Long-term management of cancer patients should not only focus on the primary tumor but also monitor for the occurrence of secondary primary tumors (SPTs) and multiple primary tumors through regular check-ups and screenings. Secondary primary tumors are defined as new independent malignant tumors that arise in different locations following treatment for an initial malignancy, and they are not recurrences or metastases of the first primary tumor. Various factors may contribute to the development of SPTs, such as age, obesity, genetic susceptibility, the stage at diagnosis of the first primary tumor, and environmental exposure. Previous studies have shown that the incidence of SPTs in cancer patients ranges from 8-16%, varying by tumor site . SPTs pose a significant threat to cancer patients' survival, accounting for 55% of cancer-related deaths .
EHA Roundtable | Professor Xiaohui Zhang’s Team Wins YoungEHA Best Abstract Award: Comprehensive Analysis of Outstanding Research Results

EHA Roundtable | Professor Xiaohui Zhang’s Team Wins YoungEHA Best Abstract Award: Comprehensive Analysis of Outstanding Research Results

2024.06.24
The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June 13-16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative concepts and the latest scientific and clinical research results in hematology. At this year's conference, Professor Xiaohui Zhang's team from Peking University People's Hospital performed outstandingly, with four studies selected for oral presentation, and one study awarded the YoungEHA Best Abstract Award, making it one of the four global award-winning studies of the year and the only one from China to receive this honor. This achievement not only highlights the team's exceptional strength but also showcases the potential and capabilities of Chinese researchers. "Oncology Frontier - Hematology Frontier" specially invited Professor Xiaohui Zhang and his team members for a roundtable discussion to share their research findings, covering non-invasive diagnostic techniques, mechanisms of CAR-T cell therapy toxicity in relapsed/refractory T-cell leukemia, prognosis models for mixed phenotype acute leukemia (MPAL), and innovative clinical research in immune thrombocytopenia (ITP).
EHA Expert Interview | Professor Jun Ma: China’s Innovative Contributions Draw Global Attention, Major Breakthroughs in AML

EHA Expert Interview | Professor Jun Ma: China’s Innovative Contributions Draw Global Attention, Major Breakthroughs in AML

2024.06.24
The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June 13-16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative concepts and the latest scientific and clinical research results in hematology. At this year's conference, Professor Jun Ma's team from the Harbin Institute of Hematology and Oncology presented real-world study results on the treatment of acute myeloid leukemia (AML) with mitoxantrone liposome. "Oncology Frontier - Hematology Frontier" invited Professor Jun Ma for an interview to interpret the study content, discuss field development trends, and introduce the outstanding performance of Chinese teams at this conference.
EASL Expert Interview | Overcoming Limitations in Liver Cancer Screening: Application and Prospects of “HelioLiver Dx” in Early Diagnosis of Liver Cancer

EASL Expert Interview | Overcoming Limitations in Liver Cancer Screening: Application and Prospects of “HelioLiver Dx” in Early Diagnosis of Liver Cancer

2024.06.24
Traditional screening methods in the field of liver cancer prevention and treatment face numerous challenges. At the 2024 European Association for the Study of the Liver (EASL) Annual Meeting, the CLiMB trial, led by Professor Richard Van Etten, Director of the UCI Chao Family Comprehensive Cancer Center in the United States, achieved significant results in the early diagnosis of hepatocellular carcinoma (HCC) in cirrhotic patients using the innovative HelioLiver Dx testing technology. This research was recognized as a breakthrough and was presented orally (Abstract No. LBO-006). HelioLiver Dx testing technology, which detects multiple epigenetic methylation markers on circulating cell-free DNA (cfDNA) and combines the analysis of various protein markers, successfully overcomes the limitations of ultrasound screening in terms of popularity and sensitivity. The study results show that HelioLiver Dx testing significantly surpasses ultrasound in sensitivity, especially in detecting small liver lesions less than 2 cm. We had an in-depth interview with Professor Van Etten and present the content for our readers.
EASL Expert Interview with Professor Frank Tacke: Interpretation of the EASL-EASD-EASO Clinical Practice Guidelines on Metabolic Associated Fatty Liver Disease

EASL Expert Interview with Professor Frank Tacke: Interpretation of the EASL-EASD-EASO Clinical Practice Guidelines on Metabolic Associated Fatty Liver Disease

2024.06.23
At the recently concluded European Association for the Study of the Liver (EASL) annual meeting, Professor Frank Tacke from Charité—Universitätsmedizin Berlin presented a special report on the newly released "Clinical Practice Guidelines for the Management of Metabolic Associated Fatty Liver Disease" by EASL, the European Association for the Study of Diabetes (EASD), and the European Association for the Study of Obesity (EASO). This guideline covers the latest recommendations from the use of non-invasive diagnostic tools to treatment strategies, emphasizing the importance of managing obesity and diabetes and the need for multidisciplinary collaboration in the management of metabolic associated fatty liver disease. At the conference, Hepatology Digest invited Professor Frank Tacke to provide an authoritative interpretation of the guideline. Professor Tacke stated that this guideline is not only a significant achievement in the field of hepatology but also a major update to the global medical community's diagnostic and treatment plans for MAFLD patients. It places a stronger emphasis on practicality and operability in clinical practice, ensuring better health outcomes for MAFLD patients.
EASL Expert Interview | Overcoming Limitations in Liver Cancer Screening: Application and Prospects of “HelioLiver Dx” in Early Diagnosis of Liver Cancer

EASL Expert Interview | Overcoming Limitations in Liver Cancer Screening: Application and Prospects of “HelioLiver Dx” in Early Diagnosis of Liver Cancer

2024.06.22
Traditional screening methods in the field of liver cancer prevention and treatment face numerous challenges. At the 2024 European Association for the Study of the Liver (EASL) Annual Meeting, the CLiMB trial, led by Professor Richard Van Etten, Director of the UCI Chao Family Comprehensive Cancer Center in the United States, achieved significant results in the early diagnosis of hepatocellular carcinoma (HCC) in cirrhotic patients using the innovative HelioLiver Dx testing technology. This research was recognized as a breakthrough and was presented orally (Abstract No. LBO-006). HelioLiver Dx testing technology, which detects multiple epigenetic methylation markers on circulating cell-free DNA (cfDNA) and combines the analysis of various protein markers, successfully overcomes the limitations of ultrasound screening in terms of popularity and sensitivity. The study results show that HelioLiver Dx testing significantly surpasses ultrasound in sensitivity, especially in detecting small liver lesions less than 2 cm. We had an in-depth interview with Professor Van Etten and present the content for our readers.
Professor Zhijie Wei: Salvage Haplo-HCT Combined with Unrelated Cord Blood Infusion Improves Survival and Reduces aGVHD in Non-Remission AML Patients

Professor Zhijie Wei: Salvage Haplo-HCT Combined with Unrelated Cord Blood Infusion Improves Survival and Reduces aGVHD in Non-Remission AML Patients

2024.06.21
The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. The EHA conference featured numerous captivating presentations, particularly in the area of non-remission acute myeloid leukemia (NR-AML), which attracted significant attention. A study by Professor Zhijie Wei's team from Beijing Lu Daopei Hospital, targeting NR-AML patients undergoing salvage haploidentical hematopoietic stem cell transplantation (haplo-HCT) (Abstract No.: P1324), was included in the conference abstracts. This study aimed to retrospectively analyze clinical and follow-up data of NR-AML patients treated with haplo-HCT at the hospital, summarizing the impact of adding unrelated cord blood infusion on patient survival and the incidence of severe (grade III-IV) graft-versus-host disease (GVHD). To provide a deeper understanding of this study, Professor Zhijie Wei was invited to give a detailed introduction, which is summarized below.
Professor Jia Wei’s Team: Exceptional Efficacy of Dual-Targeted CD19/20 CAR-T Therapy in Treating Relapsed/Refractory B-Cell Lymphoma Patients

Professor Jia Wei’s Team: Exceptional Efficacy of Dual-Targeted CD19/20 CAR-T Therapy in Treating Relapsed/Refractory B-Cell Lymphoma Patients

2024.06.21
The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it annually attracts experts and scholars from around the world to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, several studies from Professor Jia Wei's team at Tongji Hospital, Huazhong University of Science and Technology, were selected for poster or electronic poster presentations. This report highlights two studies in the field of aggressive B-cell lymphoma (P2090 and P1164), aiming to provide references for improving the long-term survival and optimizing treatment options for relapsed/refractory B-cell lymphoma.